Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Histocompatibility

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    9 result(s) found for: Histocompatibility. Displaying page 1 of 1.
    EudraCT Number: 2012-002435-28 Sponsor Protocol Number: mHagDC Start Date*: 2012-09-21
    Sponsor Name:University Medical Center Utrecht
    Full Title: A phase I/II “minor histocompatibility antigen” (mHag)-based Dendritic cell vaccination trial after allogeneic Stem Cell Transplantation to improve the safety and efficacy of donor Lymphocyte infus...
    Medical condition: Low grade, intermediate and high grade non Hodgkin lymphoma (NHL), M.Hodgkin, Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), Myelodysplasia ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004321-26 Sponsor Protocol Number: 1100.1452 Start Date*: 2006-02-17
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A Case-Control Toxicogenomics Study to identify Unique Genetic Polymorphisms in Patients who have experienced Symptomatic Hepatotoxicity or Severe Cutaneous Toxicity within the First 8 weeks of Nev...
    Medical condition: The patient population for this study will be comprised of patients with HIV-1 infection who have taken or are currently taking nevirapine and who have (cases) or have not (controls) experienced sy...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-002879-34 Sponsor Protocol Number: PSCT16 Start Date*: 2013-03-05
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Vaccination with minor histocompatibility antigen-loaded donor DC vaccines to boost graft-versus-tumor immunity after allogeneic stem cell transplantation
    Medical condition: Patients with aggressive hematological malignancies treated with allogeneic stem cell transplantation
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-005803-16 Sponsor Protocol Number: GITMOAMLR.2 Start Date*: 2007-12-24
    Sponsor Name:GITMO (GRUPPO ITALIANO DI MIDOLLLO OSSEO)
    Full Title: RANDOMIZED STUDY COMPARING INTRAVENOUS BUSULFAN (I.V. BU; BUSILVEX) PLUS FLUDARABINE (BUFLU) VERSUS INTRAVENOUS BUSULFAN PLUS CYCLOPHOSPHAMIDE (BUCY2) AS CONDITIONING REGIMENS PRIOR TO ALLOGENEIC H...
    Medical condition: Acute Myeloid Leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002214-31 Sponsor Protocol Number: XmAb5871-06 Start Date*: Information not available in EudraCT
    Sponsor Name:Xencor, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XmAb®5871 in Patients with IgG4-Related Disease (INDIGO)
    Medical condition: IgG4-Related Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10071581 IgG4 related sclerosing disease LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) NL (Prematurely Ended) SE (Prematurely Ended) BE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-002356-18 Sponsor Protocol Number: MC-FludT.14/L Start Date*: 2010-01-12
    Sponsor Name:medac Gesellschaft für klinische Spezialpräparate mbH
    Full Title: Clinical phase III trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced-intensity conditioning (RIC) prior to allogeneic haematopoietic stem cell transplantation in pa...
    Medical condition: Patients with acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) considered ineligible to standard conditioning therapies prior to allogeneic stem cell transplantation.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000881 Acute myeloid leukaemia (in remission) PT
    20.0 100000013034 10028534 Myelodysplastic syndrome NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) PL (Completed) FI (Prematurely Ended) FR (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2018-002752-33 Sponsor Protocol Number: NL.66760 Start Date*: 2019-01-17
    Sponsor Name:VU University Medical Center
    Full Title: A phase I/II trial towards the safety and efficacy of preemptive vaccination with PD-L silenced, minor histocompatibility antigen UTA2-1 peptide-loaded Dendritic Cells after Allogeneic Stem Cell Tr...
    Medical condition: Multiple Myeloma (MM), Chronic Lymphocytic Leukemia (CLL), Non hodgkin lymphoma (any grade), Acute myeloid leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    20.0 100000004864 10025311 Lymphoma (non-Hodgkin's) LLT
    20.0 100000004864 10009310 CLL LLT
    20.0 100000004864 10001941 AML LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003554-41 Sponsor Protocol Number: UTA2-1DC Start Date*: 2016-03-15
    Sponsor Name:VU University Medical Center
    Full Title: A phase I/II “minor histocompatibility antigen UTA2-1 loaded, PD-L silenced Dendritic cell vaccination trial after allogeneic Stem Cell Transplantation to improve the safety and efficacy of Donor ...
    Medical condition: Multiple Myeloma (MM), Chronic Lymphocytic Leukemia (CLL), non Hodgkin lymphoma (nHL)(any grade), Hodgkin’s lymphoma (HL).
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10020309 Hodgkin's disease, unspecified type LLT
    18.1 100000004864 10066703 Non-Hodgkin's lymphoma progression LLT
    18.1 100000004864 10028228 Multiple myeloma LLT
    18.1 100000004864 10068919 B-cell chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-022445-20 Sponsor Protocol Number: CA204006 Start Date*: 2011-11-08
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Randomized, Open Label Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma.
    Medical condition: Untreated Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) IE (Completed) GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) BE (Completed) AT (Completed) GR (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 22:26:29 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA